CLINICAL ROLE -
Advice for Physicians to Manage C. Difficile Infection (CDI)
Experts share advice for physicians taking care of patients with C. difficile infection (CDI).
SER-109, CP101, VE303 for Treatment of Recurrent C. difficile Infection (rCDI)
Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).
Challenges with Current Treatments and Emerging Treatments for C. difficile Infection (CDI)
Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).
Foundational Trials for Fecal Microbiota Transplantation for C. difficile Infection
Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.
Monitoring Patients with C. difficile Infection (CDI) and rCDI
Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).
Fecal Microbiota Transplantation (FMT) for Treatment of C. difficile Infection (CDI)
Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.
Treatment Options for C. difficile Infection (CDI)
Experts review treatment options for first, second and recurring episodes of Clostridioides difficile infection.
Long-Term Impact of C. difficile Infection (CDI) and Infection Recurrence
A gastroenterologist reviews the long-term impact of dysbiosis and Clostridioides difficile infection.
Gut Microbiota and Consequences of Gut Microbiota Disruption
Dr. Tom Lodise provides an overview of gut microbiota and the consequences of dysbiosis.
Diagnosis and Management of C. difficile Infection (CDI) in Patients with Inflammatory Bowel Disease
Dr. Abraham discusses importance of differential diagnosis of C. difficile infection (CDI) in patients with IBD and how both IBD and CDI should be managed.
Inflammatory Bowel Disease and C. difficile Infection (CDI)
A gastroenterologist, Dr. Bincy Abraham, provides an overview of C. difficile infection (CDI) in patients with inflammatory bowel disease (IBD).
Educational Opportunities to Combat C. difficile Infection (CDI)
Drs. Lodise and Feuerstadt discuss educational opportunities to combat and reduce C. difficile infection (CDI).
Preventative Measures for C. difficile Infection (CDI)
Dr. Chopra shares multipronged approach to reducing C. difficile infection (CDI) and the role of antimicrobial stewardship.
Timely Referral and Diagnosis of C. Difficile Infection (CDI)
Drs. Abraham, Chopra and Feuerstadt discuss importance of timely referral and diagnostic methods to discern C. difficile infection (CDI).
Risk Factors for Primary and Recurrent C. difficile Infection (CDI)
Drs Lodise and Feuerstadt discuss risk factors for C. difficile infection (CDI).
C. difficile and C. difficile Infection (CDI) Overview and Risk Factors for CDI
A gastroenterologist, Dr. Paul Feuerstadt, provides an overview of C. difficile infection (CDI) and vegetative and spore phases of CDI.
The Role of the Microbiome in C. difficile Infection and Its Impact on Overall Health
The first step to reducing recurrent C. difficile infections is prevention.
Five Things Pharmacists Should Know About C. difficile Infection
Pharmacists play an important role in educating patients and other health care practitioners on the signs and symptoms of C. difficile infection.
Rehospitalizations and Direct Medical Costs for cSSSI: Linezolid Versus Vancomycin
Among commercially insured patients treated with linezolid or vancomycin following cSSSI-related hospitalization, linezolid was associated with significantly lower rehospitalization rates and total direct medical costs.
2 Clarke Drive Cranbury, NJ 08512